Graham P Lidgard
Overview
Explore the profile of Graham P Lidgard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gagrat Z, Krockenberger M, Bhattacharya A, Gagrat B, Leduc C, Matter M, et al.
Cancer Prev Res (Phila)
. 2024 Jan;
17(3):119-126.
PMID: 38224564
Prevention Relevance: This study highlights performance of the next-generation mt-sDNA test, which exhibits high sensitivity and specificity for detecting colorectal cancer and APLs. This noninvasive option has potential to increase...
2.
Majumder S, Taylor W, Foote P, Berger C, Wu C, Mahoney D, et al.
Clin Cancer Res
. 2021 Feb;
27(9):2523-2532.
PMID: 33593879
Purpose: We have previously identified tissue methylated DNA markers (MDMs) associated with pancreatic ductal adenocarcinoma (PDAC). In this case-control study, we aimed to assess the diagnostic performance of plasma MDMs...
3.
Ballester V, Taylor W, Slettedahl S, Mahoney D, Yab T, Sinicrope F, et al.
Epigenomics
. 2020 Dec;
12(24):2173-2187.
PMID: 33350853
Acquired molecular changes in Lynch syndrome (LS) colorectal tumors have been largely unstudied. We identified methylated DNA markers (MDMs) for discrimination of colorectal neoplasia in LS and determined if these...
4.
Xie H, Mahoney D, Foote P, Burger K, Doering K, Taylor W, et al.
Clin Cancer Res
. 2020 Oct;
27(1):141-149.
PMID: 33028593
Purpose: We aimed to assess the concordance of colorectal cancer-associated methylated DNA markers (MDM) in primary and metastatic colorectal cancer for feasibility in detection of distantly recurrent/metastatic colorectal cancer in...
5.
Chalasani N, Ramasubramanian T, Bhattacharya A, Olson M, Edwards V D, Roberts L, et al.
Clin Gastroenterol Hepatol
. 2020 Sep;
19(12):2597-2605.e4.
PMID: 32889146
Background & Aims: Hepatocellular carcinoma (HCC) can be treated effectively if detected at an early stage. Recommended surveillance strategies for at-risk patients include ultrasound with or without α-fetoprotein (AFP), but...
6.
Limburg P, Mahoney D, Ahlquist D, Allawi H, Johnson S, Kaiser M, et al.
Cancer Epidemiol Biomarkers Prev
. 2020 May;
29(8):1570-1576.
PMID: 32467348
Background: Emerging colorectal cancer trends demonstrate increased incidence and mortality in younger populations, prompting consideration of average-risk colorectal cancer screening initiation at age 45 versus 50 years. However, screening test...
7.
Qin Y, Wu C, Taylor W, Sawas T, Burger K, Mahoney D, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7396-7404.
PMID: 31527170
Purpose: The burden of esophageal cancer continues to rise, and noninvasive screening tools are needed. Methylated DNA markers (MDM) assayed from plasma show promise in detection of other cancers. For...
8.
Majumder S, Raimondo M, Taylor W, Yab T, Berger C, Dukek B, et al.
Clin Gastroenterol Hepatol
. 2019 Jul;
18(3):676-683.e3.
PMID: 31323382
Background & Aims: Precursors of pancreatic cancer arise in the ductal epithelium; markers exfoliated into pancreatic juice might be used to detect high-grade dysplasia (HGD) and cancer. Specific methylated DNA...
9.
Majumder S, Taylor W, Yab T, Berger C, Dukek B, Cao X, et al.
Am J Gastroenterol
. 2019 Jul;
114(9):1539-1549.
PMID: 31306149
Objectives: Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia...
10.
Kisiel J, Dukek B, V S R Kanipakam R, Ghoz H, Yab T, Berger C, et al.
Hepatology
. 2018 Sep;
69(3):1180-1192.
PMID: 30168613
Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed. We aimed to identify and validate methylated DNA markers (MDMs) for HCC detection. Reduced representation bisulfite...